Among commercially insured patients treated with linezolid or vancomycin following cSSSI-related hospitalization, linezolid was associated with significantly lower rehospitalization rates and total direct medical costs.
H. Keri Yang, PhD, MPH
Advertisement
Articles by H. Keri Yang, PhD, MPH
Advertisement
Latest Updated Articles
- Rehospitalizations and Direct Medical Costs for cSSSI: Linezolid Versus Vancomycin
Published: December 13th 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
3
FDA Approves Gazyva for Active Lupus Nephritis
4
Turning the Tide in TNBC: Trop2-Targeted Therapies Improve Patient Outcomes
5
